Wisłowska M, Jabłońska B
Department of Rheumatology, Central Clinical Hospital, Woloska 137, 02-507, Warsaw, Poland.
Rheumatol Int. 2005 Jun;25(5):373-8. doi: 10.1007/s00296-004-0581-7. Epub 2005 Mar 1.
The cartilage oligomeric matrix protein (COMP) is a glycoprotein, which occurs mainly in an articular cartilage. The amount of this protein increases under the influence of cytokines and growth factors. As a result of various diseases that cause damage to cartilage, fragments of matrix protein are released into synovial fluid and then into blood. The assessment of matrix protein level in serum, for example COMP, permits the establishment of the degree of cartilage damage in inflammatory joint diseases, and permits observation of the effectiveness of the treatment. Blood was collected from 30 systemic lupus erythematosus (SLE) patients, and from 30 patients with knee osteoarthritis (OA) who constituted the control group. Serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay (ELISA). The average value of the serum COMP level in SLE patients was 11.3+/-3.7 U/l. According to correlation coefficients, serum COMP level is independent of patients' age, disease duration and the clinical picture of SLE. No correlation was found between serum COMP level and bone mass density (BMD) changes. In SLE patients with decreased haemoglobin levels (<11.0 g/dl) values compared with patients with normal haemoglobin level, the serum COMP level was observed to be significantly higher (P<0.05). Both in SLE patients with erythrocyte sedimentation rate (ESR) values over 60 mm/h and in patients with ESR values below 60 mm/h, the serum COMP level was observed to be significantly higher (P<0.05). A significant positive correlation was found between serum COMP level and ESR value, as well as a number of thrombocytes. Negative correlation occurred between the serum COMP level and the value of haemoglobin. The average value of COMP in OA patients was 10.4+/-2.7 U/l. No correlation was found between serum COMP level and patients' age and disease duration. There was correlation between the serum COMP level and the T-score value of densitometry examinations in OA patients. No statistical differences were found between the average serum COMP levels for SLE and OA patients.
软骨寡聚基质蛋白（COMP）是一种糖蛋白，主要存在于关节软骨中。该蛋白的量在细胞因子和生长因子的影响下会增加。由于各种导致软骨损伤的疾病，基质蛋白片段会释放到滑液中，进而进入血液。评估血清中基质蛋白水平，例如COMP，有助于确定炎症性关节疾病中软骨损伤的程度，并可观察治疗效果。收集了30例系统性红斑狼疮（SLE）患者以及30例构成对照组的膝骨关节炎（OA）患者的血液。使用抑制酶联免疫吸附测定（ELISA）法测定血清COMP水平。SLE患者血清COMP水平的平均值为11.3±3.7 U/l。根据相关系数，血清COMP水平与患者年龄、病程及SLE的临床表现无关。未发现血清COMP水平与骨密度（BMD）变化之间存在相关性。与血红蛋白水平正常的患者相比，血红蛋白水平降低（<11.0 g/dl）的SLE患者血清COMP水平显著更高（P<0.05）。红细胞沉降率（ESR）值超过60 mm/h的SLE患者以及ESR值低于60 mm/h的患者，血清COMP水平均显著更高（P<0.05）。血清COMP水平与ESR值以及血小板数量之间存在显著正相关。血清COMP水平与血红蛋白值之间呈负相关。OA患者COMP的平均值为10.4±2.7 U/l。未发现血清COMP水平与患者年龄和病程之间存在相关性。OA患者血清COMP水平与骨密度测量检查的T值之间存在相关性。SLE患者和OA患者的血清COMP平均水平之间未发现统计学差异。
